Scope of symptoms and self-management strategies for chemotherapy-induced peripheral neuropathy in breast cancer patients

Supportive Care in Cancer

Volumn 20, Issue 10, 2012, Pages 2433-2439

  Speck, Rebecca M ^a,b   DeMichele, Angela ^a   Farrar, John T ^a   Hennessy, Sean ^a   Mao, Jun J ^a   Stineman, Margaret G ^a   Barg, Frances K ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b 1121A Blockley Hall ^*  (United States)

Author keywords

Chemotherapy induced peripheral neuropathy; Coping strategies; Symptom management

Indexed keywords

ANTINEOPLASTIC AGENT; DOCETAXEL; PACLITAXEL; TAXANE DERIVATIVE;

ADULT; AMNESIA; ANOREXIA; ANXIETY; ARM SWELLING; ARTHRALGIA; ARTICLE; AWARENESS; BONE PAIN; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY; CLINICAL ARTICLE; CONCENTRATION LOSS; CONSTIPATION; COORDINATION; COPING BEHAVIOR; DEPRESSION; DIARRHEA; DRUG INDUCED DISEASE; DYSPNEA; ENVIRONMENTAL CHANGE; FATIGUE; FEMALE; HAIR LOSS; HAND STRENGTH; HOT FLUSH; HUMAN; INDIGESTION; LEG SWELLING; LEISURE; LIBIDO; MOUTH PAIN; MULTIPLE CYCLE TREATMENT; MUSCLE WEAKNESS; MYALGIA; NAUSEA; PAIN; PARESTHESIA; PATIENT ATTITUDE; PATIENT MOBILITY; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RASH; RESTLESSNESS; SELF CARE; SEMI STRUCTURED INTERVIEW; SIDE EFFECT; SKIN TINGLING; SMELLING DISORDER; SOCIAL LIFE; STOMACH PAIN; TASTE DISORDER; WEIGHT GAIN; WEIGHT REDUCTION; WORK;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; PACLITAXEL; PENNSYLVANIA; PERIPHERAL NERVOUS SYSTEM DISEASES; SELF CARE; TAXOIDS; YOUNG ADULT;

EID: 84868493865     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-011-1365-8     Document Type: Article

References (34)

1. Cancer trends progress report - 2009/2010 update (2010). National Cancer Institute, NIH, DHHS, Bethesda, MD. http://progressreport. cancer.gov. Accessed 3June 2011
2. Budman DR, Berry DA, Cirrincione CT, Henderson IC, Wood WC, Weiss RB et al (1998) Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B. J Natl Cancer Inst 90:1205-1211 (Pubitemid 28407086)
3. Early Breast Cancer Trialists' Collaborative Group (1998) Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 352:930-942
4. Chirivella I, Bermejo B, Insa A, Perez-Fidalgo A, Magro A, Rosello S et al (2009) Optimal delivery of anthracycline-based chemotherapy in the adjuvant setting improves outcome of breast cancer patients. Breast Cancer Res Trial 114:479-484
5. Chang J (2000) Chemotherapy dose reduction and delay in clinical practice. evaluating the risk to patient outcome in adjuvant chemotherapy for breast cancer. Eur J Cancer 36(Suppl 1):S11-S14
6. Basch E (2010) The missing voice of patients in drug-safety reporting. N Engl J Med 362:865-869
7. Wang J, Huang Y (2007) Pharmacogenomics of sex difference in chemotherapeutic toxicity. Curr Drug Discov Technol 4:59-68 (Pubitemid 47037694)
8. Erban JK, Lau J (2006) On the toxicity of chemotherapy for breast cancer - the need for vigilance. J Natl Cancer Inst 98:1096-1097 (Pubitemid 44288783)
9. Hassett MJ, O'Malley AJ, Pakes JR, Newhouse JP, Earle CC (2006) Frequency and cost of chemotherapy-related serious adverse effects in a population sample of women with breast cancer. J Natl Cancer Inst 98:1108-1117 (Pubitemid 44288785)
10. Citron ML, Berry DA, Cirrincione C, Hudis C, Winer EP, Gradishar WJ (2003) Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 21:1431-1439 (Pubitemid 46594092)
11. Moore S (2007) Managing treatment side effects in advanced breast cancer. Semin Oncol Nurs 23:S23-S30
12. Nahleh Z, Tabbara IA (2003) Complementary and alternative medicine in breast cancer patients. Palliat Support Care 1:267-273
13. Speck RM, Courneya KS, Masse LC, Duval S, Schmitz KH (2010) An update of controlled physical activity trials in cancer survivors: a systematic review and meta-analysis. J Cancer Surviv 4:87-100
14. Cavaletti G, Marmiroli P (2010) Chemotherapy-induced peripheral neurotoxicity. Nat Rev Neurol 6:657-666
15. Wolf S, Barton D, Kottschade L, Grothey A, Loprinzi C (2008) Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies. Eur J Cancer 44:1507-1515
16. Visovsky C, Collins M, Abbott L, Aschenbrenner J, Hart C (2007) Putting evidence into practice: evidence-based interventions for chemotherapy-induced peripheral neuropathy. Clin J Oncol Nurs 11:901-913
17. Bakitas MA (2007) Background noise: the experience of chemotherapy-induced peripheral neuropathy. Nurs Res 56:323- 331
18. Boehmke MM, Dickerson SS (2005) Symptom, symptom experiences, and symptom distress encountered by women with breast cancer undergoing current treatment modalities. Cancer Nurs 28:382-389 (Pubitemid 41395659)
19. Tofthagen C (2010) Patient perceptions associated with chemotherapyinduced peripheral neuropathy. Clin J Oncol Nurs 14:E22-E28
20. In: Bickman L, Rog DJ (eds) Handbook of applied social research methods. Sage Publications, Thousand Oaks, CA, pp 69-100
21. Patton M (2002) Qualitative research and evaluation methods. Sage Publications, London
22. Kemper EA, Stringfield S, Teddlie C (2003) Mixed methods sampling strategies in social science research. In: Tashakkori A, Teddlie C (eds) Handbook of mixed methods in social and behavioral research. Sage Publications, Thousand Oaks, CA, pp 273- 296
23. Paice JA (2009) Clinical challenges: chemotherapy-induced peripheral neuropathy. Semin Oncol Nurs 25:S8-S19
24. Dunlap B, Paice JA (2006) Chemotherapy-induced peripheral neuropathy: a need for standardization in measurement. J Support Oncol 4:398-399 (Pubitemid 44541015)
25. Kuroi K, Shimozuma K, Ohashi Y, Takeuchi A, Aranishi T, Morita S et al (2008) A questionnaire survey of physicians' perspectives regarding the assessment of chemotherapy-induced peripheral neuropathy in patients with breast cancer. Jpn J Clin Oncol 38:748- 754
26. National Cancer Institute (2009) Common Terminology Criteria for Adverse Events v4.0. NCI, NIH, DHHS. http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE-.03-010-06- 14-uickReference-x7. pdf. Accessed 10August 2011
27. QSR International (2008) Nvivo qualitative data analysis software version 8 edn. QSR International
28. Boeije H (2002) A purposeful approach to the constant comparative method in the analysis of qualitative interviews. Qual Quant 36:391- 409 (Pubitemid 37132934)
29. Velos I (2011) Velos eResearch. Velos, Fremont, CA
30. Sasane M, Tencer T, French A, Maro T, Beusterien KM (2010) Patient-reported outcomes in chemotherapy-induced peripheral neuropathy: a review. J Support Oncol 8:E15-E21
31. National Cancer Institute Symptom Management and Quality of Life Steering Committee: chemotherapy-induced peripheral neuropathy (2009) National Cancer Institute, Rockville, MD. http://transformingtrials.cancer.gov/files/CIPN-CTPM- Final-Executive-Summary-for-CCCT-Aug-2010.pdf. Accessed 3June 2011
32. Rothman M, Burke L, Erickson P, Leidy NK, Patrick DL, Petrie CD (2009) Use of existing patient-reported outcome (PRO) instruments and their modification: the ISPOR good research practices for evaluating and documenting content validity for the use of existing instruments and their Modification PRO task force report. Value Health 12:1075-1083
33. Webb TL, Sheeran P (2006) Does changing behavioral intentions engender behavior change? A meta-analysis of the experimental evidence. Psychol Bull 132:249-268 (Pubitemid 43439928)
34. Klesges LM, Estabrooks PA, Dzewaltowski DA, Bull SS, Glasgow RE (2005) Beginning with the application in mind: designing and planning health behavior change interventions to enhance dissemination. Ann Behav Med 29(Suppl):66-75 (Pubitemid 40586356)